Qiagen Management
Management criteria checks 4/4
Qiagen's CEO is Thierry Bernard, appointed in Oct 2019, has a tenure of 4.5 years. total yearly compensation is $1.99M, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $9.82M. The average tenure of the management team and the board of directors is 6.3 years and 9.8 years respectively.
Key information
Thierry Bernard
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 49.1% |
| CEO tenure | 4.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 6.3yrs |
| Board average tenure | 9.8yrs |
Recent management updates
Recent updates
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
Feb 13Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings
Jan 23These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued
Oct 24Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
Sep 09Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jul 17Qiagen: Major Asset Growth Needed In Post-Covid World
Jun 22Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Apr 18Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued
Feb 14Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated
Feb 07If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity
Jan 18Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases
Jan 06A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jan 04Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati
Dec 13Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M
Nov 07We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Qiagen stock down after BHF downgrades rating to Neutral
Oct 10Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Oct 04Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate
Sep 14Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
Aug 25Is Qiagen (NYSE:QGEN) Using Too Much Debt?
Jul 28Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio
Jul 15Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?
Jun 29Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
May 26Is Qiagen (NYSE:QGEN) A Risky Investment?
Apr 29Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?
Mar 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$979k | US$341m |
| Sep 30 2023 | n/a | n/a | US$485m |
| Jun 30 2023 | n/a | n/a | US$490m |
| Mar 31 2023 | n/a | n/a | US$505m |
| Dec 31 2022 | US$10m | US$950k | US$423m |
| Sep 30 2022 | n/a | n/a | US$488m |
| Jun 30 2022 | n/a | n/a | US$539m |
| Mar 31 2022 | n/a | n/a | US$563m |
| Dec 31 2021 | US$2m | US$900k | US$513m |
| Sep 30 2021 | n/a | n/a | US$311m |
| Jun 30 2021 | n/a | n/a | US$480m |
| Mar 31 2021 | n/a | n/a | US$449m |
| Dec 31 2020 | US$2m | US$900k | US$359m |
| Sep 30 2020 | n/a | n/a | US$191m |
| Jun 30 2020 | n/a | n/a | US$14m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$1m | US$650k | -US$41m |
Compensation vs Market: Thierry's total compensation ($USD1.99M) is below average for companies of similar size in the US market ($USD8.30M).
Compensation vs Earnings: Thierry's compensation has been consistent with company performance over the past year.
CEO
Thierry Bernard (58 yo)
4.5yrs
Tenure
US$1,991,874
Compensation
Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board since 2021 and had been its Interim Chief Executive Officer since Octo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Member of Management Board | 4.5yrs | US$1.99m | 0.11% $ 9.8m | |
| CFO, MD & Member of Management Board | 20.3yrs | US$1.07m | 0.16% $ 14.7m | |
| Senior VP & Head of Global Operations | 2yrs | no data | no data | |
| Vice President of Corporate Communications & Investor Relations | 13.5yrs | no data | no data | |
| Senior VP & Head of Human Resources | 4.5yrs | no data | no data | |
| Senior Vice President of Life Science Business Area | 6.3yrs | no data | no data | |
| Senior Director & Head of External Communications | no data | no data | no data | |
| Senior VP & Head of Molecular Diagnostics Business Area | 8.9yrs | no data | no data | |
| Senior Vice President of Qiagen Digital Insights Business Area | 6.3yrs | no data | no data |
6.3yrs
Average Tenure
52.5yo
Average Age
Experienced Management: QGEN's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board | 20.3yrs | US$86.50k | 0.19% $ 17.4m | |
| Independent Member of the Supervisory Board | 12.8yrs | US$101.50k | 0.022% $ 2.0m | |
| Independent Member of the Supervisory Board | 1.8yrs | US$68.50k | no data | |
| Independent Chairman of Supervisory Board | 10.8yrs | US$188.50k | 0.0067% $ 625.0k | |
| Independent Member of the Supervisory Board | 3.3yrs | US$82.50k | 0.0012% $ 110.3k | |
| Independent Member of the Supervisory Board | 9.8yrs | US$79.50k | 0.0019% $ 171.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board | 8.3yrs | US$68.50k | 0.0076% $ 701.0k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data |
9.8yrs
Average Tenure
63yo
Average Age
Experienced Board: QGEN's board of directors are considered experienced (9.8 years average tenure).